FDA confirms single pivotal trial path for ATH434 in MSA
Alterity Therapeutics received official meeting minutes from the FDA confirming that a single pivotal Phase 3 trial plus confirmatory evidence could support approval of ATH434 for the treatment of Multiple System Atrophy (MSA). The FDA agreed with the proposed Phase 3 trial design, including the primary endpoint of the 11-item UMSARS Part I rating scale. The Phase 3 study is expected to enroll approximately 200 patients and is on track to initiate by year-end 2026.
*this image is generated using AI for illustrative purposes only.
Alterity Therapeutics received official meeting minutes from the U.S. Food and Drug Administration (FDA) confirming that a single pivotal Phase 3 trial plus confirmatory evidence could support approval of ATH434 for the treatment of Multiple System Atrophy (MSA). The minutes confirm the key elements of the registrational Phase 3 program and the path toward a potential New Drug Application (NDA) filing. Pivotal Phase 3 trial activities remain on track to initiate by year-end 2026.
The FDA agreed with the proposed Phase 3 trial design, including the study population, treatment regimen, and efficacy endpoints. Alignment was reached on the selection and analysis of the primary endpoint, the 11-item UMSARS Part I rating scale, a functional measure of activities of daily living affected in MSA. Agreement was also reached on key secondary endpoints, including the Swallowing Disturbance Questionnaire (SDQ), the Orthostatic Hypertension Symptom Assessment (OHSA), and the Clinical Global Impression of Severity (CGI-S).
Alterity expects that data from its ATH434-201 Phase 2 clinical trial will provide the required confirmatory evidence to support the NDA. The FDA indicated that the anticipated size of Alterity’s safety database at the conclusion of the Phase 3 trial was reasonable. The Company plans to offer an open label extension to participants who complete the Phase 3 trial to continue their treatment and enhance the safety database for ATH434.
Phase 3 Trial Design
The Phase 3 study is expected to enroll approximately 200 patients. Participants will be randomized in a 1:1 ratio and treated with ATH434 50 mg or matching placebo twice daily for 12 months.
| Parameter | Details |
|---|---|
| Patients | Approximately 200 |
| Randomization | 1:1 ratio |
| Dosage | 50 mg or placebo twice daily |
| Duration | 12 months |
| Primary Endpoint | 11-item UMSARS Part I rating scale |
ATH434 is an oral agent designed to reduce iron accumulation and inhibit abnormal protein aggregation associated with neurodegeneration. It has been granted Fast Track Designation by the FDA and Orphan Drug Designation by the FDA and the European Commission for the treatment of MSA.
How might the FDA's acceptance of a single pivotal trial plus confirmatory evidence influence the regulatory strategies of other biotech firms developing treatments for rare neurodegenerative diseases?
What are the potential commercial and competitive implications for ATH434 if the Phase 2 trial data successfully serves as confirmatory evidence, potentially accelerating the NDA timeline?
How will the open-label extension study impact the long-term safety profile and market positioning of ATH434 compared to other MSA treatments in development?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
